200 related articles for article (PubMed ID: 19962759)
21. Exposure-Response Analysis of Alvocidib (Flavopiridol) Treatment by Bolus or Hybrid Administration in Newly Diagnosed or Relapsed/Refractory Acute Leukemia Patients.
LaCerte C; Ivaturi V; Gobburu J; Greer JM; Doyle LA; Wright JJ; Karp JE; Rudek MA
Clin Cancer Res; 2017 Jul; 23(14):3592-3600. PubMed ID: 28174232
[No Abstract] [Full Text] [Related]
22. Mitoxantrone and cytosine arabinoside as treatment for acute myelogenous leukemia (AML) at first recurrence.
MacCallum PK; Davis CL; Rohatiner AZ; Lim J; Gupta RK; Whelan JS; Price CG; Evans ML; Amess JA; Leahy M
Leukemia; 1993 Oct; 7(10):1496-9. PubMed ID: 8412309
[TBL] [Abstract][Full Text] [Related]
23. A randomized comparison of intensive maintenance treatment for adult acute myelogenous leukemia using either cyclic alternating drugs or repeated courses of the induction-type chemotherapy: AML-6 trial of the EORTC Leukemia Cooperative Group.
Jehn U; Zittoun R; Suciu S; Fiere D; Haanen C; Peetermans M; Löwenberg B; Willemze R; Solbu G; Stryckmans P
Haematol Blood Transfus; 1990; 33():277-84. PubMed ID: 1691132
[TBL] [Abstract][Full Text] [Related]
24. Intermediate-dose Ara-C/m-AMSA for remission induction and high-dose Ara-C/m-AMSA for intensive consolidation in relapsed and refractory adult acute myelogeneous leukemia.
Jehn U; Heinemann V
Haematol Blood Transfus; 1990; 33():333-8. PubMed ID: 1691134
[TBL] [Abstract][Full Text] [Related]
25. In vivo purging with high-dose cytarabine followed by high-dose chemoradiotherapy and reinfusion of unpurged bone marrow for adult acute myelogenous leukemia in first complete remission.
Stein AS; O'Donnell MR; Chai A; Schmidt GM; Nademanee A; Parker PM; Smith EP; Snyder DS; Molina A; Stepan DE; Spielberger R; Somlo G; Margolin KA; Vora N; Lipsett J; Lee J; Niland J; Forman SJ
J Clin Oncol; 1996 Aug; 14(8):2206-16. PubMed ID: 8708709
[TBL] [Abstract][Full Text] [Related]
26. Timed-sequential chemotherapy with concomitant granulocyte colony-stimulating factor for newly diagnosed de novo acute myelogenous leukemia.
He XY; Pohlman B; Lichtin A; Rybicki L; Kalaycio M
Leukemia; 2003 Jun; 17(6):1078-84. PubMed ID: 12764371
[TBL] [Abstract][Full Text] [Related]
27. Multicenter randomized phase II trial of idarubicin vs mitoxantrone, combined with VP-16 and cytarabine for induction/consolidation therapy, followed by a feasibility study of autologous peripheral blood stem cell transplantation in elderly patients with acute myeloid leukemia.
Archimbaud E; Jehn U; Thomas X; De Cataldo F; Fillet G; Belhabri A; Peaud PY; Martin C; Amadori S; Willemze R
Leukemia; 1999 Jun; 13(6):843-9. PubMed ID: 10360370
[TBL] [Abstract][Full Text] [Related]
28. Clinical activity of alvocidib (flavopiridol) in acute myeloid leukemia.
Zeidner JF; Karp JE
Leuk Res; 2015 Dec; 39(12):1312-8. PubMed ID: 26521988
[TBL] [Abstract][Full Text] [Related]
29. [Intensification chemotherapy followed by allogenieic and autologous bone marrow transplantation in acute non-lymphoblastic leukemia in children].
Ortega Aramburu JJ; Olivé Oliveras T; Javier Manchón G; Bastida Vila P; Sánchez C; Giralt López J
Sangre (Barc); 1991 Feb; 36(1):7-14. PubMed ID: 1853274
[TBL] [Abstract][Full Text] [Related]
30. High-dose cytosine arabinoside and mitoxantrone: a highly effective regimen in refractory acute myeloid leukemia.
Hiddemann W; Kreutzmann H; Straif K; Ludwig WD; Mertelsmann R; Donhuijsen-Ant R; Lengfelder E; Arlin Z; Büchner T
Blood; 1987 Mar; 69(3):744-9. PubMed ID: 3469002
[TBL] [Abstract][Full Text] [Related]
31. Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group.
Büchner T; Hiddemann W; Wörmann B; Löffler H; Gassmann W; Haferlach T; Fonatsch C; Haase D; Schoch C; Hossfeld D; Lengfelder E; Aul C; Heyll A; Maschmeyer G; Ludwig WD; Sauerland MC; Heinecke A
Blood; 1999 Jun; 93(12):4116-24. PubMed ID: 10361108
[TBL] [Abstract][Full Text] [Related]
32. Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukemia Group.
Wierzbowska A; Robak T; Pluta A; Wawrzyniak E; Cebula B; Hołowiecki J; Kyrcz-Krzemień S; Grosicki S; Giebel S; Skotnicki AB; Piatkowska-Jakubas B; Kuliczkowski K; Kiełbiński M; Zawilska K; Kłoczko J; Wrzesień-Kuś A;
Eur J Haematol; 2008 Feb; 80(2):115-26. PubMed ID: 18076637
[TBL] [Abstract][Full Text] [Related]
33. Effect of priming with granulocyte-macrophage colony-stimulating factor in younger adults with newly diagnosed acute myeloid leukemia: a trial by the Acute Leukemia French Association (ALFA) Group.
Thomas X; Raffoux E; Botton Sd; Pautas C; Arnaud P; de Revel T; Reman O; Terré C; Corront B; Gardin C; Le QH; Quesnel B; Cordonnier C; Bourhis JH; Elhamri M; Fenaux P; Preudhomme C; Michallet M; Castaigne S; Dombret H
Leukemia; 2007 Mar; 21(3):453-61. PubMed ID: 17252021
[TBL] [Abstract][Full Text] [Related]
34. Sequential standard dose mitoxantrone and cytosine arabinoside for newly diagnosed adult acute myeloblastic leukemia.
Al Bahar S; Pandita R; Bavishi K; Savani B
Neoplasma; 1999; 46(1):61-5. PubMed ID: 10355536
[TBL] [Abstract][Full Text] [Related]
35. Sequential response-adapted induction and consolidation regimens idarubicin/cytarabine and mitoxantrone/etoposide in adult acute myelogenous leukemia: 10 year follow-up of a study by the Canadian Leukemia Studies Group.
Van Der Jagt R; Robinson KS; Belch A; Yetisir E; Wells G; Larratt L; Shustik C; Gluck S; Stewart K; Sheridan D;
Leuk Lymphoma; 2006 Apr; 47(4):697-706. PubMed ID: 16690529
[TBL] [Abstract][Full Text] [Related]
36. Clinical and laboratory studies of 2-chlorodeoxyadenosine +/- cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults.
Kornblau SM; Gandhi V; Andreeff HM; Beran M; Kantarjian HM; Koller CA; O'Brien S; Plunkett W; Estey E
Leukemia; 1996 Oct; 10(10):1563-9. PubMed ID: 8847890
[TBL] [Abstract][Full Text] [Related]
37. Granulocyte colony-stimulating factor following chemotherapy in elderly patients with newly diagnosed acute myelogenous leukemia.
Maslak PG; Weiss MA; Berman E; Yao TJ; Tyson D; Golde DW; Scheinberg DA
Leukemia; 1996 Jan; 10(1):32-9. PubMed ID: 8558934
[TBL] [Abstract][Full Text] [Related]
38. Time sequential chemotherapy for primary refractory or relapsed adult acute myeloid leukemia: results of the phase II Gemia protocol.
Martino R; Guardia R; Altés A; Sureda A; Brunet S; Sierra J
Haematologica; 1999 Mar; 84(3):226-30. PubMed ID: 10189387
[TBL] [Abstract][Full Text] [Related]
39. High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk acute myeloid leukemia (AML).
Larson SM; Campbell NP; Huo D; Artz A; Zhang Y; Gajria D; Green M; Weiner H; Daugherty C; Odenike O; Godley LA; Hyjek E; Gurbuxani S; Thirman M; Sipkins D; Van Besien K; Larson RA; Stock W
Leuk Lymphoma; 2012 Mar; 53(3):445-50. PubMed ID: 21913806
[TBL] [Abstract][Full Text] [Related]
40. Treatment of patients with recurrent and primary refractory acute myelogenous leukemia using mitoxantrone and intermediate-dose cytarabine: a pharmacologically based regimen.
Sternberg DW; Aird W; Neuberg D; Thompson L; MacNeill K; Amrein P; Shulman LN
Cancer; 2000 May; 88(9):2037-41. PubMed ID: 10813714
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
